LivaNova PLC Announces Participation in 30th EACTS Annual Meeting
September 30 2016 - 9:00AM
LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) (“LivaNova” or the
“Company”), a market-leading medical technology company, announced
today its participation in the 30th European Association for
Cardio-Thoracic Surgery (EACTS) Annual Meeting, October 1 – 5,
2016, in Barcelona, Spain.
At its exhibit and Tecnosuite in the CCBI
Conference Center, LivaNova will celebrate several major patient
treatment milestones for its Cardiac Surgery Business Unit and
discuss the Company’s campaign to “Cut Through Complexity” using
simplified procedures and enabling better outcomes.
On Monday, October 3, 2016, LivaNova will host
the lunch symposium “Aortic and Mitral Experiences Across the
Oceans” from 12:45 p.m. until 2:00 p.m. in Meeting Room 111. The
symposium will feature a case presentation on mitral valve repair
and a case presentation on aortic valve replacement. On
Monday evening, October 3, 2016, the Company is conducting another
symposium — not affiliated with EACTS — titled “Cut Through
Complexity: Simplified Procedures, Better Outcomes” from 6:30 p.m.
until 9:30 p.m. at Can Magi in Barcelona. Topics include
sutureless aortic valve replacement, mitral valve repair with
semi-rigid ring technology and innovations for future
interventions.
Major 2016 milestones that LivaNova will be
sharing with attendees include:
- More than 20,000 patients treated with the PERCEVAL™
bioprosthetic aortic valve
- 30 years from the first implant of a CARBOMEDICSTM aortic
valve
- More than 500,000 patients treated with INSPIRETM
oxygenators
- 10 years of clinical use for FREEDOM SOLOTM stentless aortic
valves with excellent hemodynamic performance and long-term
durability
“LivaNova is focused on innovating technology to
help advance cardiac surgery methods and approaches,” said Jim
Trevor, General Manager, Cardiac Surgery, LivaNova PLC.
“Through our participation in EACTS, we’re demonstrating how
our efforts to cut through complexity can help achieve improved
patient care, safety, recovery and survival as well as help ensure
efficient allocation of hospital resources.”
About LivaNovaLivaNova PLC is a global medical
technology company formed by the merger of Sorin S.p.A, a leader in
the treatment of cardiovascular diseases, and Cyberonics Inc., a
medical device company with core expertise in
neuromodulation. LivaNova transforms medical innovation into
meaningful solutions for the benefit of patients, healthcare
professionals, and healthcare systems. The Company employs
approximately 4,600 employees worldwide and is headquartered in
London, U.K. With a presence in more than 100 countries,
LivaNova operates as three business units: Cardiac Surgery, Cardiac
Rhythm Management, and Neuromodulation, with operating headquarters
in Clamart (France), Mirandola (Italy) and Houston (U.S.),
respectively.
LivaNova is listed on NASDAQ and is admitted to
the standard listing segment of the Official List of the UK’s
Financial Conduct Authority and to trading on the London Stock
Exchange (LSE) under the ticker symbol “LIVN”.
Safe Harbor StatementThis press release contains
forward-looking statements within the meaning of Section 21E of the
United States Securities Exchange Act of 1934, as amended.
Forward-looking statements are not historical facts but are based
on certain assumptions of management and describe our future plans,
strategies and expectations. Forward-looking statements can
generally be identified by the use of forward-looking terminology,
including, but not limited to, "may," “could,” “seek,” “guidance,”
“predict,” “potential,” “likely,” "believe," "will," "expect,"
"anticipate," "estimate," "plan," "intend," "forecast," or
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Forward-looking
statements contained in this press release are based on information
presently available to LivaNova and assumptions that LivaNova
believes to be reasonable, but are inherently uncertain. As a
result, our actual results, performance or achievements may differ
materially from those expressed or implied by these forward-looking
statements. Investors are cautioned that all such statements
involve risks and uncertainties, including without limitation, the
factors described in the “Risk Factors” section of LivaNova’s
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and other documents filed from time to
time with, and/or announced or published pursuant to the rules of,
the United States Securities and Exchange Commission and/or the
United Kingdom Financial Conduct Authority by LivaNova, together
with the risk that our internal leadership and organizational
realignment will not lead to intended improvements, efficiency or
results. This list of factors is not exhaustive.
LivaNova does not give any assurance (1) that LivaNova will achieve
its expectations, or (2) concerning any result or the timing
thereof.
All information in this press release is as of
the date of its release. LivaNova does not undertake or
assume any obligation to update publicly any of the forward-looking
statements in this press release to reflect actual results, new
information or future events, changes in assumptions or changes in
other factors affecting forward-looking statements, except to the
extent required by applicable law. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements. We caution you not to place undue
reliance on any forward-looking statements, which are made only as
of the date of this press release.
For more information, please
visit www.livanova.com, or contact:
Investor Relations and
MediaKaren KingVice President, Investor Relations &
Corporate CommunicationsPhone: +1 (281) 228-7262Fax: +1 (281)
218-9332e-mail: corporate.communications@livanova.com
Livanova (LSE:LIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Livanova (LSE:LIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024